Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Osteoporosis: the emperor has no clothes
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Orthopaedics.
2015 (English)In: Journal of Internal Medicine, ISSN 0954-6820, E-ISSN 1365-2796, Vol. 277, no 6, 662-73 p.Article in journal (Refereed) Published
Abstract [en]

UNLABELLED: Current prevention strategies for low-trauma fractures amongst older persons depend on the notions that fractures are mainly caused by osteoporosis (pathophysiology), that patients at high risk can be identified (screening) and that the risk is amenable to bone-targeted pharmacotherapy (treatment). However, all these three notions can be disputed.

PATHOPHYSIOLOGY: Most fracture patients have fallen, but actually do not have osteoporosis. A high likelihood of falling, in turn, is attributable to an ageing-related decline in physical functioning and general frailty.

SCREENING: Currently available fracture risk prediction strategies including bone densitometry and multifactorial prediction tools are unable to identify a large proportion of patients who will sustain a fracture, whereas many of those with a high fracture risk score will not sustain a fracture.

TREATMENT: The evidence for the viability of bone-targeted pharmacotherapy in preventing hip fracture and other clinical fragility fractures is mainly limited to women aged 65-80 years with osteoporosis, whereas the proof of hip fracture-preventing efficacy in women over 80 years of age and in men at all ages is meagre or absent. Further, the antihip fracture efficacy shown in clinical trials is absent in real-life studies. Many drugs for the treatment of osteoporosis have also been associated with increased risks of serious adverse events. There are also considerable uncertainties related to the efficacy of drug therapy in preventing clinical vertebral fractures, whereas the efficacy for preventing other fractures (relative risk reductions of 20-25%) remains moderate, particularly in terms of the low absolute risk reduction in fractures with this treatment.

Place, publisher, year, edition, pages
2015. Vol. 277, no 6, 662-73 p.
National Category
Orthopedics
Identifiers
URN: urn:nbn:se:uu:diva-253694DOI: 10.1111/joim.12366ISI: 000355000400004PubMedID: 25809279OAI: oai:DiVA.org:uu-253694DiVA: diva2:815583
Available from: 2015-06-01 Created: 2015-06-01 Last updated: 2017-12-04Bibliographically approved

Open Access in DiVA

fulltext(1072 kB)117 downloads
File information
File name FULLTEXT01.pdfFile size 1072 kBChecksum SHA-512
bfb632d6aca6b17055ce0fc6149b585ac72db001b80fd9f3190e66cf3d075b288acbe090714ecaea2be1379cd4e7180eea9667dc665dbb0c698446cee6c883c9
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records BETA

Michaëlsson, Karl

Search in DiVA

By author/editor
Michaëlsson, Karl
By organisation
Orthopaedics
In the same journal
Journal of Internal Medicine
Orthopedics

Search outside of DiVA

GoogleGoogle Scholar
Total: 117 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 500 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf